Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Mutations in Nucleophosmin 1 (NPM1) are associated with a favorable prognosis in newly diagnosed acute myeloid leukemia (AML), however, their prognostic impact in relapsed/refractory (R/R) settings are unknown. In a retrospective analysis, we identified 206 patients (12%) with mutated NPM1 (NPM1c) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Issa, Ghayas C., Bidikian, Aram, Venugopal, Sangeetha, Konopleva, Marina, DiNardo, Courtney D., Kadia, Tapan M., Borthakur, Gautam, Jabbour, Elias, Pemmaraju, Naveen, Yilmaz, Musa, Short, Nicholas J., Maiti, Abhishek, Sasaki, Koji, Masarova, Lucia, Pierce, Sherry, Takahashi, Koichi, Tang, Guilin, Loghavi, Sanam, Patel, Keyur, Andreeff, Michael, Bhalla, Kapil, Garcia-Manero, Guillermo, Ravandi, Farhad, Kantarjian, Hagop, Daver, Naval
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027507/
https://www.ncbi.nlm.nih.gov/pubmed/36322818
http://dx.doi.org/10.1182/bloodadvances.2022008316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027507/
https://www.ncbi.nlm.nih.gov/pubmed/36322818
http://dx.doi.org/10.1182/bloodadvances.2022008316

Ejemplares similares